{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T14:09:17Z","timestamp":1776866957743,"version":"3.51.2"},"reference-count":17,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T00:00:00Z","timestamp":1762300800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Tislelizumab, a humanized IgG4 anti-programmed cell death 1 (PD-1) monoclonal antibody approved in China in 2019 for advanced solid tumors such as esophageal cancer, functions by blocking the PD-1\/PD-L1 pathway to reactivate anti-tumor immunity. Common adverse reactions include fever and rash; however, toxic epidermal necrolysis (TEN)\u2014a rare, life-threatening drug hypersensitivity reaction\u2014is reported in fewer than 0.1% of patients receiving PD-1 inhibitors, with limited real-world evidence specifically linking it to tislelizumab.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case presentation<\/jats:title>\n                    <jats:p>A 70-year-old male with esophageal squamous cell carcinoma received two cycles of neoadjuvant therapy (nab-paclitaxel, cisplatin, and tislelizumab 200 mg) followed by partial esophagectomy. On day 86 after the first tislelizumab infusion, he developed a diffuse rash progressing to skin exfoliation, vesiculation, and a positive Nikolsky sign, leading to a diagnosis of TEN. Upon admission, his SCORTEN was 3 (predicting 35% mortality) and ALDEN score was 5, indicating a probable association with tislelizumab. Management included intravenous methylprednisolone, immunoglobulin, topical treatments, and nutritional support. The patient achieved complete recovery two months after symptom onset.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This case illustrates that tislelizumab can induce TEN after a prolonged incubation period (86 days in this instance). It underscores the importance of vigilant monitoring of skin and mucous membranes during treatment, early recognition and intervention, and adequate glucocorticoid dosing in managing this serious immune-related adverse event, offering valuable clinical insight for oncologists.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2025.1707956","type":"journal-article","created":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T05:20:44Z","timestamp":1762320044000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Tislelizumab-associated toxic epidermal necrolysis in an esophageal cancer patient: a case report"],"prefix":"10.3389","volume":"16","author":[{"given":"Sha","family":"Jin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zehu","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fengming","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,11,5]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1482005","article-title":"Perioperative tislelizumab with four cycles of neoadjuvant chemotherapy for resectable locally advanced esophageal squamous cell carcinoma: a phase 2 study","volume":"15","author":"Zhou","year":"2024","journal-title":"Front Immunol"},{"key":"B2","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1186\/s12943-021-01489-2","article-title":"Combination strategies with PD-1\/PD-L1 blockade: current advances and future directions","volume":"21","author":"Yi","year":"2022","journal-title":"Mol Cancer"},{"key":"B3","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1007\/s40265-020-01286-z","article-title":"Tislelizumab: first approval","volume":"80","author":"Lee","year":"2020","journal-title":"Drugs"},{"key":"B4","doi-asserted-by":"publisher","first-page":"1651","DOI":"10.1001\/jamaoncol.2023.4003","article-title":"Tislelizumab vs sorafenib as first-line treatment for unresectable hepatocellular carcinoma: A phase 3 randomized clinical trial","volume":"9","author":"Qin","year":"2023","journal-title":"JAMA Oncol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1111\/ddg.14118","article-title":"Erythema multiforme, Stevens-Johnson syndrome\/toxic epidermal necrolysis - diagnosis and treatment","volume":"18","author":"Grunwald","year":"2020","journal-title":"J Dtsch Dermatol Ges"},{"key":"B6","doi-asserted-by":"publisher","first-page":"2097","DOI":"10.1080\/14796694.2024.2345043","article-title":"Development of perioperative immune checkpoint inhibitor therapy for locally advanced esophageal squamous cell carcinoma","volume":"20","author":"Kadono","year":"2024","journal-title":"Future Oncol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1016\/S1470-2045(23)00108-0","article-title":"Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first-line treatment for advanced or metastatic oesophageal squamous cell carcinoma (RATIONALE-306): a global, randomised, placebo-controlled, phase 3 study","volume":"24","author":"Xu","year":"2023","journal-title":"Lancet Oncol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"2545","DOI":"10.2217\/fon-2020-1222","article-title":"Immune-related adverse events with PD-1 versus PD-L1 inhibitors: a meta-analysis of 8730 patients from clinical trials","volume":"17","author":"Sonpavde","year":"2021","journal-title":"Future Oncol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2017.00049","article-title":"Current diagnosis and management of immune related adverse events (irAEs) induced by immune checkpoint inhibitor therapy","volume":"8","author":"Kumar","year":"2017","journal-title":"Front Pharmacol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1111\/ddg.15150","article-title":"Toxic epidermal necrolysis post apalutamide with preceding tislelizumab administration in a patient with two cancers","volume":"21","author":"Wu","year":"2023","journal-title":"J Dtsch Dermatol Ges"},{"key":"B11","doi-asserted-by":"publisher","first-page":"10733","DOI":"10.1038\/s41467-024-54180-7","article-title":"Immune checkpoint inhibitor-induced severe epidermal necrolysis mediated by macrophage-derived CXCL10 and abated by TNF blockade","volume":"15","author":"Chen","year":"2024","journal-title":"Nat Commun"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2025.08.027","article-title":"Analysis of skin immune cells in stevens-johnson syndrome and toxic epidermal necrolysis","author":"Clatch","year":"2025","journal-title":"J Invest Dermatol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1016\/j.jaip.2022.01.038","article-title":"Evaluation of combination therapy with etanercept and systemic corticosteroids for stevens-johnson syndrome and toxic epidermal necrolysis: A multicenter observational study","volume":"10","author":"Zhang","year":"2022","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B14","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.jtos.2025.06.004","article-title":"Attribution of causality in Stevens-Johnson syndrome\/toxic epidermal necrolysis","volume":"38","author":"Parvathaneni","year":"2025","journal-title":"Ocul Surf"},{"key":"B15","doi-asserted-by":"publisher","first-page":"1448","DOI":"10.1111\/ddg.15515","article-title":"S3 guideline: Diagnosis and treatment of epidermal necrolysis (Stevens-Johnson syndrome and toxic epidermal necrolysis) - Part 1: Diagnosis, initial management, and immunomodulating systemic therapy","volume":"22","author":"Heuer","year":"2024","journal-title":"J Dtsch Dermatol Ges"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD013130.pub2","article-title":"Systemic interventions for treatment of Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS\/TEN overlap syndrome","volume":"3","author":"Jacobsen","year":"2022","journal-title":"Cochrane Database Syst Rev"},{"key":"B17","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1001\/jamadermatol.2023.0035","article-title":"Evaluation of plasmapheresis vs immunoglobulin as first treatment after ineffective systemic corticosteroid therapy for patients with stevens-johnson syndrome and toxic epidermal necrolysis","volume":"159","author":"Miyamoto","year":"2023","journal-title":"JAMA Dermatol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1707956\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T05:20:45Z","timestamp":1762320045000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1707956\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,5]]},"references-count":17,"alternative-id":["10.3389\/fimmu.2025.1707956"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1707956","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,5]]},"article-number":"1707956"}}